Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc has entered a strategic collaboration with Tempus AI to enhance its AI-driven drug development in oncology. This partnership will provide Avacta access to Tempus’ extensive datasets for better understanding tumor biology, aiming to optimize its pre|CISION® platform and target specific cancer patient populations. This collaboration reflects Avacta’s commitment to advancing precision medicine and improving outcomes for cancer patients.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
